A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety and Tolerability of MEDI3506 in Participants with Moderate to Severe Chronic Obstructive Pulmonary Disease and Chronic Bronchitis (FRONTIER 4)

ClinicalTrials.gov Identifier: NCT04631016

This is a research study to determine the efficacy and safety of investigational drug MEDI3506 for the treatment of adult subjects with Chronic Obstructive Pulmonary Disease and Chronic Bonchitis.

Study details

Categories:

Human Clinical Trail

PROTOCOL NO.: Ajinomoto AminoIndex™ 2015-01

TITLE: A Case-Control Study to Verify Diagnostic Performance of AminoIndex™ Technology

This is a prospective, multi-center study to evaluate the diagnostic performance characteristics of the AminoIndex™ technology among patients at high risk of developing lung cancer as compared with standard lung cancer screening and diagnostic procedures including low-dose CT, high-dose CT, biopsy, and histopathology.

Learn More

A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the Long-Term Safety of GSK3511294 in Participants with Severe Asthma with an Eosinophilic Phenotype

ClinicalTrials.gov Identifier: NCT04718103

This study will assess the efficacy and safety of GSK3511294 as an adjunctive therapy in participants with severe uncontrolled asthma with an eosinophilic phenotype despite standard of care (SoC) treatment with medium to high dose inhaled corticosteroid (ICS) plus at least one additional controller.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib Administered Once Daily for 52 Weeks in Subjects with Non-Cystic Fibrosis Bronchiectasis – The ASPEN Study

ClinicalTrials.gov Identifier: NCT04594369

The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period.

A Phase III Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Prm-151 in Patients with Idiopathic Pulmonary Fibrosis

ClinicalTrials.gov Identifier: NCT04552899

This phase III study will evaluate the efficacy, safety and pharmacokinetics (PK) of recombinant human pentraxin-2 (rhPTX-2; PRM-151) compared with placebo in participants with idiopathic pulmonary fibrosis (IPF).

Learn More

ARISE – A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)

ClinicalTrials.gov Identifier: NCT04677543

The primary objective of this study is to generate evidence demonstrating the domain specification via modern psychometric methods, reliability, validity, and responsiveness of Quality of Life – Bronchiectasis (QoL-B) and Patient-Reported Outcome Measurement Information System – Fatigue-Short Form (PROMIS F-SF 7a) in participants with newly diagnosed nontuberculous mycobacterial (NTM) lung infection caused by Myobaxterium avium Complex (MAC).

A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of an Amikacin Liposome Inhalation Suspension (ALIS)-Based Regimen in Adult Subjects with Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium avium Complex (MAC)

ClinicalTrials.gov Identifier: NCT04677569

The main objective of this study is to evaluate the efficacy of ALIS (amikacin liposome inhalation suspension) + Azithromycin + Ethambutol compared to the ELC (empty liposome control) + Azithromycin + Ethambutol on participant reported respiratory symptoms at Month 13.

______________________________________

SEER-Lung: A Prospective Blood Sample Collection Study to Develop and Validate a Panel of Protein-based Biomarkers in Patients with Pulmonary Nodules

The objective of this study is to develop a panel of blood-based protein biomarkers for the characterization of lung nodules in patients with intermediate risk lung nodules considered for biopsy. This is a prospective, multicenter minimal-risk sample collection study that will develop and validate the accuracy of a blood-based panel of protein biomarkers for use in patients with lung nodules who are considered for biopsy.

Future Enrolling Studies

  • Asthma

  • COPD

  • Bronchiectasis

  • Lung cancer

  • Pulmonary hypertension

  • Atrial fibrillation

  • CAD

  • Rheumatoid arthritis

  • Hyperlipidemia

  • Heart failure